The global market for Antitumor Peptide Drugs was valued at US$ 6735 million in the year 2024 and is projected to reach a revised size of US$ 14430 million by 2031, growing at a CAGR of 11.7% during the forecast period.

Antitumor Peptide Drugs Market

Antitumor peptide drugs are a class of innovative cancer therapeutics designed based on short-chain amino acid sequences. These peptide drugs exert their antitumor effects through various mechanisms, including inhibiting cancer cell proliferation, inducing apoptosis, disrupting tumor angiogenesis, and enhancing the body's immune response against cancer. Compared to traditional chemotherapy drugs, peptide-based therapies typically offer higher specificity, lower toxicity, and better biocompatibility. Moreover, due to their relatively simple structure, peptides are easier to synthesize and modify, making them a popular area of research in cancer treatment. Currently, some antitumor peptide drugs have entered clinical application, such as LHRH (luteinizing hormone-releasing hormone) analogs, cell-penetrating peptides (CPPs), and antimicrobial peptide (AMP)-based anticancer agents, offering new hope for cancer therapy.

North American market for Antitumor Peptide Drugs is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Antitumor Peptide Drugs is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Antitumor Peptide Drugs include Ipsen, Novartis, AstraZeneca, AbbVie, Ferring Pharmaceuticals, Tolmar, Foresee Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Antitumor Peptide Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antitumor Peptide Drugs.

The Antitumor Peptide Drugs market size, estimations, and forecasts are provided in terms of sales volume (kg) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Antitumor Peptide Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Antitumor Peptide Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Antitumor Peptide Drugs Market Report

Report Metric	Details
Report Name	Antitumor Peptide Drugs Market
Accounted market size in year	US$ 6735 million
Forecasted market size in 2031	US$ 14430 million
CAGR	11.7%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Lanreotide Octreotide Goserelin Leuprolide Degarelix
Segment by Application	Hospital Clinic Others
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Ipsen, Novartis, AstraZeneca, AbbVie, Ferring Pharmaceuticals, Tolmar, Foresee Pharmaceuticals
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Antitumor Peptide Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Antitumor Peptide Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Antitumor Peptide Drugs Market growing?

Ans: The Antitumor Peptide Drugs Market witnessing a CAGR of 11.7% during the forecast period 2025-2031.

What is the Antitumor Peptide Drugs Market size in 2031?

Ans: The Antitumor Peptide Drugs Market size in 2031 will be US$ 14430 million.

Who are the main players in the Antitumor Peptide Drugs Market report?

Ans: The main players in the Antitumor Peptide Drugs Market are Ipsen, Novartis, AstraZeneca, AbbVie, Ferring Pharmaceuticals, Tolmar, Foresee Pharmaceuticals

What are the Application segmentation covered in the Antitumor Peptide Drugs Market report?

Ans: The Applications covered in the Antitumor Peptide Drugs Market report are Hospital, Clinic, Others

What are the Type segmentation covered in the Antitumor Peptide Drugs Market report?

Ans: The Types covered in the Antitumor Peptide Drugs Market report are Lanreotide, Octreotide, Goserelin, Leuprolide, Degarelix

1 Antitumor Peptide Drugs Market Overview

1.1 Product Definition

1.2 Antitumor Peptide Drugs by Type

1.2.1 Global Antitumor Peptide Drugs Market Value Comparison by Type (2024 VS 2031)

1.2.2 Lanreotide

1.2.3 Octreotide

1.2.4 Goserelin

1.2.5 Leuprolide

1.2.6 Degarelix

1.3 Antitumor Peptide Drugs by Application

1.3.1 Global Antitumor Peptide Drugs Market Value by Application (2024 VS 2031)

1.3.2 Hospital

1.3.3 Clinic

1.3.4 Others

1.4 Global Antitumor Peptide Drugs Market Size Estimates and Forecasts

1.4.1 Global Antitumor Peptide Drugs Revenue 2020-2031

1.4.2 Global Antitumor Peptide Drugs Sales 2020-2031

1.4.3 Global Antitumor Peptide Drugs Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 Antitumor Peptide Drugs Market Competition by Manufacturers

2.1 Global Antitumor Peptide Drugs Sales Market Share by Manufacturers (2020-2025)

2.2 Global Antitumor Peptide Drugs Revenue Market Share by Manufacturers (2020-2025)

2.3 Global Antitumor Peptide Drugs Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of Antitumor Peptide Drugs, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Antitumor Peptide Drugs, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Antitumor Peptide Drugs, Product Type & Application

2.7 Global Key Manufacturers of Antitumor Peptide Drugs, Date of Enter into This Industry

2.8 Global Antitumor Peptide Drugs Market Competitive Situation and Trends

2.8.1 Global Antitumor Peptide Drugs Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Antitumor Peptide Drugs Players Market Share by Revenue

2.8.3 Global Antitumor Peptide Drugs Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Antitumor Peptide Drugs Market Scenario by Region

3.1 Global Antitumor Peptide Drugs Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global Antitumor Peptide Drugs Sales by Region: 2020-2031

3.2.1 Global Antitumor Peptide Drugs Sales by Region: 2020-2025

3.2.2 Global Antitumor Peptide Drugs Sales by Region: 2026-2031

3.3 Global Antitumor Peptide Drugs Revenue by Region: 2020-2031

3.3.1 Global Antitumor Peptide Drugs Revenue by Region: 2020-2025

3.3.2 Global Antitumor Peptide Drugs Revenue by Region: 2026-2031

3.4 North America Antitumor Peptide Drugs Market Facts & Figures by Country

3.4.1 North America Antitumor Peptide Drugs Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America Antitumor Peptide Drugs Sales by Country (2020-2031)

3.4.3 North America Antitumor Peptide Drugs Revenue by Country (2020-2031)

3.4.4 United States

3.4.5 Canada

3.5 Europe Antitumor Peptide Drugs Market Facts & Figures by Country

3.5.1 Europe Antitumor Peptide Drugs Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe Antitumor Peptide Drugs Sales by Country (2020-2031)

3.5.3 Europe Antitumor Peptide Drugs Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Antitumor Peptide Drugs Market Facts & Figures by Region

3.6.1 Asia Pacific Antitumor Peptide Drugs Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific Antitumor Peptide Drugs Sales by Region (2020-2031)

3.6.3 Asia Pacific Antitumor Peptide Drugs Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Antitumor Peptide Drugs Market Facts & Figures by Country

3.7.1 Latin America Antitumor Peptide Drugs Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America Antitumor Peptide Drugs Sales by Country (2020-2031)

3.7.3 Latin America Antitumor Peptide Drugs Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.7.7 Colombia

3.8 Middle East and Africa Antitumor Peptide Drugs Market Facts & Figures by Country

3.8.1 Middle East and Africa Antitumor Peptide Drugs Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa Antitumor Peptide Drugs Sales by Country (2020-2031)

3.8.3 Middle East and Africa Antitumor Peptide Drugs Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Antitumor Peptide Drugs Sales by Type (2020-2031)

4.1.1 Global Antitumor Peptide Drugs Sales by Type (2020-2025)

4.1.2 Global Antitumor Peptide Drugs Sales by Type (2026-2031)

4.1.3 Global Antitumor Peptide Drugs Sales Market Share by Type (2020-2031)

4.2 Global Antitumor Peptide Drugs Revenue by Type (2020-2031)

4.2.1 Global Antitumor Peptide Drugs Revenue by Type (2020-2025)

4.2.2 Global Antitumor Peptide Drugs Revenue by Type (2026-2031)

4.2.3 Global Antitumor Peptide Drugs Revenue Market Share by Type (2020-2031)

4.3 Global Antitumor Peptide Drugs Price by Type (2020-2031)

5 Segment by Application

5.1 Global Antitumor Peptide Drugs Sales by Application (2020-2031)

5.1.1 Global Antitumor Peptide Drugs Sales by Application (2020-2025)

5.1.2 Global Antitumor Peptide Drugs Sales by Application (2026-2031)

5.1.3 Global Antitumor Peptide Drugs Sales Market Share by Application (2020-2031)

5.2 Global Antitumor Peptide Drugs Revenue by Application (2020-2031)

5.2.1 Global Antitumor Peptide Drugs Revenue by Application (2020-2025)

5.2.2 Global Antitumor Peptide Drugs Revenue by Application (2026-2031)

5.2.3 Global Antitumor Peptide Drugs Revenue Market Share by Application (2020-2031)

5.3 Global Antitumor Peptide Drugs Price by Application (2020-2031)

6 Key Companies Profiled

6.1 Ipsen

6.1.1 Ipsen Company Information

6.1.2 Ipsen Description and Business Overview

6.1.3 Ipsen Antitumor Peptide Drugs Sales, Revenue and Gross Margin (2020-2025)

6.1.4 Ipsen Antitumor Peptide Drugs Product Portfolio

6.1.5 Ipsen Recent Developments/Updates

6.2 Novartis

6.2.1 Novartis Company Information

6.2.2 Novartis Description and Business Overview

6.2.3 Novartis Antitumor Peptide Drugs Sales, Revenue and Gross Margin (2020-2025)

6.2.4 Novartis Antitumor Peptide Drugs Product Portfolio

6.2.5 Novartis Recent Developments/Updates

6.3 AstraZeneca

6.3.1 AstraZeneca Company Information

6.3.2 AstraZeneca Description and Business Overview

6.3.3 AstraZeneca Antitumor Peptide Drugs Sales, Revenue and Gross Margin (2020-2025)

6.3.4 AstraZeneca Antitumor Peptide Drugs Product Portfolio

6.3.5 AstraZeneca Recent Developments/Updates

6.4 AbbVie

6.4.1 AbbVie Company Information

6.4.2 AbbVie Description and Business Overview

6.4.3 AbbVie Antitumor Peptide Drugs Sales, Revenue and Gross Margin (2020-2025)

6.4.4 AbbVie Antitumor Peptide Drugs Product Portfolio

6.4.5 AbbVie Recent Developments/Updates

6.5 Ferring Pharmaceuticals

6.5.1 Ferring Pharmaceuticals Company Information

6.5.2 Ferring Pharmaceuticals Description and Business Overview

6.5.3 Ferring Pharmaceuticals Antitumor Peptide Drugs Sales, Revenue and Gross Margin (2020-2025)

6.5.4 Ferring Pharmaceuticals Antitumor Peptide Drugs Product Portfolio

6.5.5 Ferring Pharmaceuticals Recent Developments/Updates

6.6 Tolmar

6.6.1 Tolmar Company Information

6.6.2 Tolmar Description and Business Overview

6.6.3 Tolmar Antitumor Peptide Drugs Sales, Revenue and Gross Margin (2020-2025)

6.6.4 Tolmar Antitumor Peptide Drugs Product Portfolio

6.6.5 Tolmar Recent Developments/Updates

6.7 Foresee Pharmaceuticals

6.7.1 Foresee Pharmaceuticals Company Information

6.7.2 Foresee Pharmaceuticals Description and Business Overview

6.7.3 Foresee Pharmaceuticals Antitumor Peptide Drugs Sales, Revenue and Gross Margin (2020-2025)

6.7.4 Foresee Pharmaceuticals Antitumor Peptide Drugs Product Portfolio

6.7.5 Foresee Pharmaceuticals Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Antitumor Peptide Drugs Industry Chain Analysis

7.2 Antitumor Peptide Drugs Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Antitumor Peptide Drugs Production Mode & Process Analysis

7.4 Antitumor Peptide Drugs Sales and Marketing

7.4.1 Antitumor Peptide Drugs Sales Channels

7.4.2 Antitumor Peptide Drugs Distributors

7.5 Antitumor Peptide Drugs Customer Analysis

8 Antitumor Peptide Drugs Market Dynamics

8.1 Antitumor Peptide Drugs Industry Trends

8.2 Antitumor Peptide Drugs Market Drivers

8.3 Antitumor Peptide Drugs Market Challenges

8.4 Antitumor Peptide Drugs Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Ferring Pharmaceuticals

Tolmar

Foresee Pharmaceuticals

List of Tables

Table 1. Global Antitumor Peptide Drugs Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global Antitumor Peptide Drugs Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global Antitumor Peptide Drugs Market Competitive Situation by Manufacturers in 2024

Table 4. Global Antitumor Peptide Drugs Sales (kg) of Key Manufacturers (2020-2025)

Table 5. Global Antitumor Peptide Drugs Sales Market Share by Manufacturers (2020-2025)

Table 6. Global Antitumor Peptide Drugs Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global Antitumor Peptide Drugs Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market Antitumor Peptide Drugs Average Price (US$/g) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of Antitumor Peptide Drugs, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Antitumor Peptide Drugs, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Antitumor Peptide Drugs, Product Type & Application

Table 12. Global Key Manufacturers of Antitumor Peptide Drugs, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Antitumor Peptide Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antitumor Peptide Drugs as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Antitumor Peptide Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global Antitumor Peptide Drugs Sales by Region (2020-2025) & (kg)

Table 18. Global Antitumor Peptide Drugs Sales Market Share by Region (2020-2025)

Table 19. Global Antitumor Peptide Drugs Sales by Region (2026-2031) & (kg)

Table 20. Global Antitumor Peptide Drugs Sales Market Share by Region (2026-2031)

Table 21. Global Antitumor Peptide Drugs Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global Antitumor Peptide Drugs Revenue Market Share by Region (2020-2025)

Table 23. Global Antitumor Peptide Drugs Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global Antitumor Peptide Drugs Revenue Market Share by Region (2026-2031)

Table 25. North America Antitumor Peptide Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America Antitumor Peptide Drugs Sales by Country (2020-2025) & (kg)

Table 27. North America Antitumor Peptide Drugs Sales by Country (2026-2031) & (kg)

Table 28. North America Antitumor Peptide Drugs Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America Antitumor Peptide Drugs Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe Antitumor Peptide Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe Antitumor Peptide Drugs Sales by Country (2020-2025) & (kg)

Table 32. Europe Antitumor Peptide Drugs Sales by Country (2026-2031) & (kg)

Table 33. Europe Antitumor Peptide Drugs Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe Antitumor Peptide Drugs Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific Antitumor Peptide Drugs Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific Antitumor Peptide Drugs Sales by Region (2020-2025) & (kg)

Table 37. Asia Pacific Antitumor Peptide Drugs Sales by Region (2026-2031) & (kg)

Table 38. Asia Pacific Antitumor Peptide Drugs Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific Antitumor Peptide Drugs Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America Antitumor Peptide Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America Antitumor Peptide Drugs Sales by Country (2020-2025) & (kg)

Table 42. Latin America Antitumor Peptide Drugs Sales by Country (2026-2031) & (kg)

Table 43. Latin America Antitumor Peptide Drugs Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America Antitumor Peptide Drugs Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa Antitumor Peptide Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa Antitumor Peptide Drugs Sales by Country (2020-2025) & (kg)

Table 47. Middle East and Africa Antitumor Peptide Drugs Sales by Country (2026-2031) & (kg)

Table 48. Middle East and Africa Antitumor Peptide Drugs Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa Antitumor Peptide Drugs Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global Antitumor Peptide Drugs Sales (kg) by Type (2020-2025)

Table 51. Global Antitumor Peptide Drugs Sales (kg) by Type (2026-2031)

Table 52. Global Antitumor Peptide Drugs Sales Market Share by Type (2020-2025)

Table 53. Global Antitumor Peptide Drugs Sales Market Share by Type (2026-2031)

Table 54. Global Antitumor Peptide Drugs Revenue (US$ Million) by Type (2020-2025)

Table 55. Global Antitumor Peptide Drugs Revenue (US$ Million) by Type (2026-2031)

Table 56. Global Antitumor Peptide Drugs Revenue Market Share by Type (2020-2025)

Table 57. Global Antitumor Peptide Drugs Revenue Market Share by Type (2026-2031)

Table 58. Global Antitumor Peptide Drugs Price (US$/g) by Type (2020-2025)

Table 59. Global Antitumor Peptide Drugs Price (US$/g) by Type (2026-2031)

Table 60. Global Antitumor Peptide Drugs Sales (kg) by Application (2020-2025)

Table 61. Global Antitumor Peptide Drugs Sales (kg) by Application (2026-2031)

Table 62. Global Antitumor Peptide Drugs Sales Market Share by Application (2020-2025)

Table 63. Global Antitumor Peptide Drugs Sales Market Share by Application (2026-2031)

Table 64. Global Antitumor Peptide Drugs Revenue (US$ Million) by Application (2020-2025)

Table 65. Global Antitumor Peptide Drugs Revenue (US$ Million) by Application (2026-2031)

Table 66. Global Antitumor Peptide Drugs Revenue Market Share by Application (2020-2025)

Table 67. Global Antitumor Peptide Drugs Revenue Market Share by Application (2026-2031)

Table 68. Global Antitumor Peptide Drugs Price (US$/g) by Application (2020-2025)

Table 69. Global Antitumor Peptide Drugs Price (US$/g) by Application (2026-2031)

Table 70. Ipsen Company Information

Table 71. Ipsen Description and Business Overview

Table 72. Ipsen Antitumor Peptide Drugs Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)

Table 73. Ipsen Antitumor Peptide Drugs Product

Table 74. Ipsen Recent Developments/Updates

Table 75. Novartis Company Information

Table 76. Novartis Description and Business Overview

Table 77. Novartis Antitumor Peptide Drugs Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)

Table 78. Novartis Antitumor Peptide Drugs Product

Table 79. Novartis Recent Developments/Updates

Table 80. AstraZeneca Company Information

Table 81. AstraZeneca Description and Business Overview

Table 82. AstraZeneca Antitumor Peptide Drugs Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)

Table 83. AstraZeneca Antitumor Peptide Drugs Product

Table 84. AstraZeneca Recent Developments/Updates

Table 85. AbbVie Company Information

Table 86. AbbVie Description and Business Overview

Table 87. AbbVie Antitumor Peptide Drugs Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)

Table 88. AbbVie Antitumor Peptide Drugs Product

Table 89. AbbVie Recent Developments/Updates

Table 90. Ferring Pharmaceuticals Company Information

Table 91. Ferring Pharmaceuticals Description and Business Overview

Table 92. Ferring Pharmaceuticals Antitumor Peptide Drugs Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)

Table 93. Ferring Pharmaceuticals Antitumor Peptide Drugs Product

Table 94. Ferring Pharmaceuticals Recent Developments/Updates

Table 95. Tolmar Company Information

Table 96. Tolmar Description and Business Overview

Table 97. Tolmar Antitumor Peptide Drugs Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)

Table 98. Tolmar Antitumor Peptide Drugs Product

Table 99. Tolmar Recent Developments/Updates

Table 100. Foresee Pharmaceuticals Company Information

Table 101. Foresee Pharmaceuticals Description and Business Overview

Table 102. Foresee Pharmaceuticals Antitumor Peptide Drugs Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)

Table 103. Foresee Pharmaceuticals Antitumor Peptide Drugs Product

Table 104. Foresee Pharmaceuticals Recent Developments/Updates

Table 105. Key Raw Materials Lists

Table 106. Raw Materials Key Suppliers Lists

Table 107. Antitumor Peptide Drugs Distributors List

Table 108. Antitumor Peptide Drugs Customers List

Table 109. Antitumor Peptide Drugs Market Trends

Table 110. Antitumor Peptide Drugs Market Drivers

Table 111. Antitumor Peptide Drugs Market Challenges

Table 112. Antitumor Peptide Drugs Market Restraints

Table 113. Research Programs/Design for This Report

Table 114. Key Data Information from Secondary Sources

Table 115. Key Data Information from Primary Sources

Table 116. Authors List of This Report

List of Figures

Figure 1. Product Picture of Antitumor Peptide Drugs

Figure 2. Global Antitumor Peptide Drugs Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Antitumor Peptide Drugs Market Share by Type: 2024 & 2031

Figure 4. Lanreotide Product Picture

Figure 5. Octreotide Product Picture

Figure 6. Goserelin Product Picture

Figure 7. Leuprolide Product Picture

Figure 8. Degarelix Product Picture

Figure 9. Global Antitumor Peptide Drugs Market Value by Application (2020-2031) & (US$ Million)

Figure 10. Global Antitumor Peptide Drugs Market Share by Application: 2024 & 2031

Figure 11. Hospital

Figure 12. Clinic

Figure 13. Others

Figure 14. Global Antitumor Peptide Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 15. Global Antitumor Peptide Drugs Market Size (2020-2031) & (US$ Million)

Figure 16. Global Antitumor Peptide Drugs Sales (2020-2031) & (kg)

Figure 17. Global Antitumor Peptide Drugs Average Price (US$/g) & (2020-2031)

Figure 18. Antitumor Peptide Drugs Report Years Considered

Figure 19. Antitumor Peptide Drugs Sales Share by Manufacturers in 2024

Figure 20. Global Antitumor Peptide Drugs Revenue Share by Manufacturers in 2024

Figure 21. Global 5 and 10 Largest Antitumor Peptide Drugs Players: Market Share by Revenue in Antitumor Peptide Drugs in 2024

Figure 22. Antitumor Peptide Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 23. Global Antitumor Peptide Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 24. North America Antitumor Peptide Drugs Sales Market Share by Country (2020-2031)

Figure 25. North America Antitumor Peptide Drugs Revenue Market Share by Country (2020-2031)

Figure 26. United States Antitumor Peptide Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 27. Canada Antitumor Peptide Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 28. Europe Antitumor Peptide Drugs Sales Market Share by Country (2020-2031)

Figure 29. Europe Antitumor Peptide Drugs Revenue Market Share by Country (2020-2031)

Figure 30. Germany Antitumor Peptide Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 31. France Antitumor Peptide Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 32. U.K. Antitumor Peptide Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 33. Italy Antitumor Peptide Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 34. Russia Antitumor Peptide Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 35. Asia Pacific Antitumor Peptide Drugs Sales Market Share by Region (2020-2031)

Figure 36. Asia Pacific Antitumor Peptide Drugs Revenue Market Share by Region (2020-2031)

Figure 37. China Antitumor Peptide Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 38. Japan Antitumor Peptide Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 39. South Korea Antitumor Peptide Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. India Antitumor Peptide Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. Australia Antitumor Peptide Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 42. China Taiwan Antitumor Peptide Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 43. Southeast Asia Antitumor Peptide Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 44. Latin America Antitumor Peptide Drugs Sales Market Share by Country (2020-2031)

Figure 45. Latin America Antitumor Peptide Drugs Revenue Market Share by Country (2020-2031)

Figure 46. Mexico Antitumor Peptide Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 47. Brazil Antitumor Peptide Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 48. Argentina Antitumor Peptide Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 49. Colombia Antitumor Peptide Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 50. Middle East and Africa Antitumor Peptide Drugs Sales Market Share by Country (2020-2031)

Figure 51. Middle East and Africa Antitumor Peptide Drugs Revenue Market Share by Country (2020-2031)

Figure 52. Turkey Antitumor Peptide Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 53. Saudi Arabia Antitumor Peptide Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 54. UAE Antitumor Peptide Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 55. Global Sales Market Share of Antitumor Peptide Drugs by Type (2020-2031)

Figure 56. Global Revenue Market Share of Antitumor Peptide Drugs by Type (2020-2031)

Figure 57. Global Antitumor Peptide Drugs Price (US$/g) by Type (2020-2031)

Figure 58. Global Sales Market Share of Antitumor Peptide Drugs by Application (2020-2031)

Figure 59. Global Revenue Market Share of Antitumor Peptide Drugs by Application (2020-2031)

Figure 60. Global Antitumor Peptide Drugs Price (US$/g) by Application (2020-2031)

Figure 61. Antitumor Peptide Drugs Value Chain

Figure 62. Channels of Distribution (Direct Vs Distribution)

Figure 63. Bottom-up and Top-down Approaches for This Report

Figure 64. Data Triangulation

Figure 65. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Peptide Based Vaccines for Cancer Market Research Report 2025

Peptide Cancer Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Peptide Vaccine for Tumor Market Research Report 2024

Global Tumor Targeting Peptides Market Research Report 2024

Global Adjuvant Peptide Market Research Report 2024

Global Peptide Therapy Market Research Report 2025

Global GnRHa Peptide Drugs Market Research Report 2024

Global Leuprolide Market Research Report 2024

Global Recombinant Protein Peptide Drug Market Research Report 2024

Global Anticancer Drugs Market Research Report 2025

Global Peptide based Generics Market Research Report 2024

Global Polypeptide Vaccine Market Research Report 2024

Global Peptide and Oligonucleotide Drugs Market Research Report 2024

Global Diabetes Peptide Drugs Market Research Report 2025

Global Leuprorelin Drugs Market Research Report 2024

Peptide Based Drug Delivery System Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Targeted Antitumor Drugs Market Research Report 2025

Peptide based Injectable Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Peptide Therapeutics Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions